cells

Multiple Cancer Types Trials

Multiple Cancer Types
(Domvanalimab + Zimberelimab)

Overview

Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies.

Key Eligibility Criteria

  • Pathologically confirmed non-small cell lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, breast cancer, colorectal cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or gastroesophageal cancer that is metastatic, advanced, or recurrent with progression for which no alternative or curative therapy exists or standard therapy is not considered appropriate by the participant and treating physicianEastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • No prior malignancy active within the previous year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer

Domvanalimab + Zimberelimab Clinical Trial Locations

clinicaltrials.gov

arrow

Multiple Cancer Types
(AB308 + zimberelimab; ARC-12 study)

Overview

A Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab in participants with advanced malignancies.

Key Eligibility Criteria

  • Participants must have performance score of 0 or 1 with measurable disease as per radiographic evaluation
  • Disease specific criteria for dose escalation includes participants with any type of solid tumor for which no treatment is currently available, or participants with non-Hodgkin Lymphoma that has progressed on prior chemotherapy and are unable to receive stem cell transplant or adoptive cell transfer. Participants may have received up to 5 prior anti-cancer therapies and an unlimited number of prior hormonal therapies.
  • No prior treatments with an anti-TIGIT antibody, active or prior autoimmune disease that required treatment in past 3 years or prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.

AB308 + zimberelimab Clinical Trial Locations

clinicaltrials.gov

arrow